Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial

INTRODUCTION: Chronic cough is a highly problematic symptom for patients with idiopathic pulmonary fibrosis (IPF); limited therapeutic options are available. We evaluated gefapixant, a P2X3 receptor antagonist, for the treatment of chronic cough in IPF. METHODS: This randomized, double-blind, placeb...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, Fernando J., Afzal, Amna Sadaf, Smith, Jaclyn A., Ford, Anthony P., Li, Jerry Jing, Li, Yuping, Kitt, Michael M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589896/
https://www.ncbi.nlm.nih.gov/pubmed/34152585
http://dx.doi.org/10.1007/s41030-021-00162-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589896/
https://www.ncbi.nlm.nih.gov/pubmed/34152585
http://dx.doi.org/10.1007/s41030-021-00162-9

Ejemplares similares